I am a
Home I AM A Search Login

Papers of the Week

2020 Sep

Transl Cancer Res



PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study.


Wei Q, Yuan X, Li J, Xu Q, Ying J
Transl Cancer Res. 2020 Sep; 9(9):5315-5322.
PMID: 35117897.


Nivolumab and pembrolizumab were approved as immune checkpoint inhibitors for third-line treatment of advanced gastric or esophagogastric junction cancer (GC/EGJC) in 2017. However, immunotherapy monotherapy has low efficacy. Apatinib has been proven effective in advanced GC/EGJC. Numerous studies have shown that immunotherapy has a synergistic effect when combined with targeted drug therapy. Based on these facts and to assess the efficacy and safety of programmed death 1 (PD-1) inhibitor and apatinib as combination therapy in patients (pts) with unresectable locally advanced or metastatic GC/EGJC, a retrospective clinical research study was carried out.